ArticleCancer causes & control : CCC2010
B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece.
Article in Cancer causes & control : CCC, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- The Critical Role of Adipocytes in Leukemia.Biology · 2025Review
- Diet patterns, gut microbiota and metabolic disorders: Perspectives and challenges.Metabolism open · 2024Article
- Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges.Current obesity reports · 2024Review
- Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges.International journal of molecular sciences · 2023Review
- Diagnostic and Prognostic Value of Serum Omentin-1 in Sepsis: A Prospective Study in Critically Ill Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Perspectives in vaccines, immune response, therapeutic interventions and COVID-19.Metabolism open · 2023Article
- Could exercise hormone irisin be a therapeutic agent against Parkinson's and other neurodegenerative diseases?Metabolism open · 2023Article
- TheMetabolism open · 2022Review
- Of mice and men: Considerations on adipose tissue physiology in animal models of obesity and human studies.Metabolism open · 2022Article
- Review
- Understanding the enigmatic association between mycosis fungoides and psoriasis: Report of two cases and review of the literature.Metabolism open · 2021Review
- Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations.Current obesity reports · 2020Review
- Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.Current obesity reports · 2018Review
- Leptin and its receptor in hematologic malignancies.International journal of clinical and experimental medicine · 2015Review
- Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.Endocrine reviews · 2013Review
- Adiponectin, driver or passenger on the road to insulin sensitivity?Molecular metabolism · 2013Review
- Serum adiponectin and resistin levels in de novo and relapsed acute lymphoblastic leukemia children patients.Iranian journal of public health · 2013Article
- Role of adiponectin and its receptors in cancer.Cancer biology & medicine · 2012Article
- The role of adiponectin in cancer: a review of current evidence.Endocrine reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
aimLeptin and adiponectin are two well-studied adipokines in relation to malignancies. In this study, we examined the association between leptin/adiponectin and risk of B-cell chronic lymphocytic leukemia (B-CLL), as well as the relationships between adipokines and several established prognostic factors of B-CLL.
methodsNinety-five patients with incident B-CLL and 95 hospital controls matched on age and gender were studied between 2001 and 2007, and blood samples were collected. Leptin, total and high molecular weight adiponectin, and prognostic markers of B-CLL were determined.
resultsCases had a higher body mass index (BMI) than controls (p = 0.01) and lower levels of leptin (p < 0.01). Significantly more cases than controls presented a family history of lymphohematopoietic cancer (LHC) (p = 0.01). Higher serum leptin levels were associated with lower risk of B-CLL adjusting for age, gender, family history of LHC, BMI and serum adiponectin; the multivariate odds ratio comparing highest to lowest tertile was 0.05 (95% CI 0.01-0.29, p trend < 0.001); Adiponectin was not significantly different between cases and controls.
conclusionLeptin was found to be inversely associated with risk of CLL but in contrast to prior studies of CLL and hematologic malignancies, this study found no significant association between CLL and adiponectin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.